ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1233

Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis

Aviya Lanis1, Emily Steelquist2, Christian Lood3 and Susan Shenoi4, 1Seattle Children's Hospital, Seattle, WA, 2OHSU, Portland, OR, 3Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, 4Seattle Children's Hospital and Research Center, Mercer Island, WA, WA

Meeting: ACR Convergence 2024

Keywords: Juvenile idiopathic arthritis, mental health, Myositis, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Children with juvenile dermatomyositis (JDM) and juvenile idiopathic arthritis (JIA) have impaired quality of life and increased rates of anxiety and depression (15-65%), even in disease remission, when compared to healthy children. Narrative medicine is a group-based intervention that allows patients to reconstruct medical experiences through written or oral self-reflective perspectives. It has demonstrated improved patient-reported outcomes with reduced rates of depression in adults but there is limited data in pediatric rheumatology. This explorative study assesses the feasibility of a patient-targeted narrative medicine intervention and its impact on mental health burden in JDM and JIA.

Methods: We prospectively recruited patients ages 6 to with JDM and JIA for a narrative medicine intervention. Participants were divided by diagnosis and age into four narrative medicine groups, with 4-6 patients per narrative medicine session. Six sessions were held over 3 months by two trained facilitators per group. Demographic and medical information were collected by chart review. To assess mental health, patients completed pre- and post-intervention questionnaires including Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Scale, Generalized Anxiety Disorder-7 (GAD-7), Childhood Attitude Towards Illness Scale (CATIS), Patient Health Questionnaire-8 (PHQ-8), and CoVID Stress Scale (CSSQ).

Results: Twelve patients with JDM (67 % female) and nine with JIA (78% female; 4 persistent oligoarticular JIA, 3 RF-negative, 1 psoriatic JIA and 1 enthesitis-related arthritis) participated in the narrative medicine intervention. All patients participated in at least 50% of sessions (Figure 1). Pre-intervention, 58% of patients with JDM and 67% of patients with JIA had inactive disease, while post-intervention 70% of patients with JDM and 55% of patients with JIA had inactive disease (Table 1). Wilcoxon signed-rank test revealed no statistically significant difference between pre- and post-intervention questionnaires for any of the scales. Sub-analysis of those with elevated GAD-7 and PHQ-8 pre-intervention showed trend towards improvement in anxiety (p=0.057) and no change for depression (p=0.171).

Conclusion: All patients participated in at least 50% of narrative medicine sessions, demonstrating feasibility. This exploratory study showed trend toward improved anxiety following narrative medicine session participation for those with elevated GAD7 but did not demonstrate significant changes in PHQ-8, PROMIS depression, CSSQ or CATIS scales likely due to small numbers and low level of mental health issues in those that participated in this study.

Supporting image 1

Table 1: Pre- and post-intervention questionnaires for patients with juvenile idiopathic arthritis and juvenile dermatomyositis. JDM = Juvenile Dermatomyositis. JIA = Juvenile Idiopathic Arthritis. PHQ-8 = Patient Health Questionnaire-8. GAD-7=Generalized Anxiety Disorder-7. CATIS=Childhood Attitude Towards Illness Scale. CSSQ=COVID Student Stress Questionnaire.

Supporting image 2

Figure 1: Number of narrative medicine intervention sessions attended by enrolled JDM and JIA participants.


Disclosures: A. Lanis: None; E. Steelquist: None; C. Lood: Amytryx, 5, Boehringer-Ingelheim, 5, Citryll, 2, Eli Lilly, 5, Exagen Inc, 2, Gilead Sciences, 5, Horizon Diagnostics, 5, Pfizer, 5, Redd Pharma, 2, 4, 5, 11; S. Shenoi: cabletta, 2, Cure JM Foundation, 12, COE support at SCH, Pfizer, 2.

To cite this abstract in AMA style:

Lanis A, Steelquist E, Lood C, Shenoi S. Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/narrative-medicine-intervention-for-mental-wellbeing-in-juvenile-myositis-and-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/narrative-medicine-intervention-for-mental-wellbeing-in-juvenile-myositis-and-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology